Arovella Therapeutics names acting CEO
Key points
- Arovella Therapeutics has appointed Dr Nicole Van Der Weerden as its acting CEO.
- The leadership transition accompanies strong operational milestones, including patient dosing and manufacturing completed in the last six months.
- Dr Van Der Weerden will receive a base salary of $401,700 plus superannuation with short- and long-term incentive options.
Arovella Therapeutics (ASX:ALA) appointed Dr Nicole Van Der Weerden as its Acting CEO.
The executive change follows recent operational progress, including product manufacturing for dosing, enrolling six clinical trial hospitals, and dosing the first patient.
"Arovella is now a clinical-stage company, and I am proud to be leading it at this pivotal time as we deliver on our objectives," said Arovella Therapeutics Acting CEO Dr Nicole Van Der Weerden.
Under the updated terms, Dr Van Der Weerden receives a base salary of A$401,700 plus superannuation, alongside eligibility for short-term and long-term incentive bonuses capped at 40% of her salary each.
Following the announcement, the Arovella Therapeutics share price was unchanged at $0.05.
Dr Van Der Weerden joined Arovella Therapeutics as COO in 2023.
Prior to her role at Arovella Therapeutics, she spent over 18 years at Hexima across CEO, COO, and non-executive director roles.
Frequently asked questions
More from Australia
Forte Energy enters South American oil exploration agreement
Pathkey.AI validates Chipforge platform through independent testing
Ingenia Communities rejects new Warburg Pincus buyback offer
Legend Mining starts drilling at Pinnacle Well Project
Koonenberry Gold advances mineral exploration across NSW projects
Greenwing Resources secures deal for San Jorge Project
